@article {Kreutzer:December 2004:1610-0379:992,
author = "Kreutzer, Katharina",
author = "Bonnekoh, Bernd",
author = "Franke, Ingolf",
author = "Gollnick, Harald",
title = "Photodynamische Therapie mit Methylaminooxopentanoat (Metvix) und einer Breitbandlichtquelle (PhotoDyn 501): Praktische Erfahrungen bei Problem-Patienten mit Aktinischen Keratosen und Basalzellkarzinomen: Photodynamic therapy with methylaminooxopentanoate (Metvix) and a broad band light source (PhotoDyn 501): Experiences in complicated patients with actinic keratoses and basal cell carcinomas",
journal = "Journal der Deutschen Dermatologischen Gesellschaft",
volume = "2",
year = "December 2004",
abstract = "Summary Background: Actinic keratoses (AK) and basal cell carcinomas (BCC) may represent a therapeutic challenge because of special subtypes, location, previous therapy or accompanying diseases. Photodynamic therapy (PDT) offers a semi-conservative treatment option for selected indications. Patients and methods: 28 outpatients who had been admitted as complicated dermato-oncologic cases because of AK (n = 22) and BCC (n = 6) were treated with PDT, using methylaminooxopentanoate (MAOP, Methyl-Ala, Metvix®) and a broad band light source (PhotoDyn 501). The treatment was evaluated for efficacy and subjective tolerance (local discomfort and pain). Results: A complete remission (CR) was achieved in 11/22 AK (50 %) and 4/6 BCC (67 %) cases. All three cases of a superficial BCC subtype underwent a CR. Among responders, tolerance was good in 12/15 cases (80 %), as compared to 4/13 cases (31 %) in non-responders. Focusing on 16/28 patients with good tolerance (57 %), there was a CR in 12 cases (75 % rate), whereas for the 12/28 patients with moderate to poor tolerance a CR was achieved in only 3 cases (25 % rate). In a subgroup of 8 patients who, partly due to secondary diseases, were taking systemic retinoids or immunosuppressive-cytostatic medications, a CR was achieved in 3/8 cases (38 %) with a good tolerance in only 1/8 cases (13 %). Conclusion: These observations confirm a good efficacy and tolerance of PDT in ≥ 50 % of a AK/BCC problem patient cohort. We found indications for 1) a positive correlation between efficacy and subjective tolerance as well as 2) the presumptive existence of a retinoid-dependent cutaneous PDT hyperalgesia. Effective pain control seems to be an essential cofactor for the success of PDT.",
pages = "992-999(8)",
url = "http://www.ingentaconnect.com/content/bsc/ddg/2004/00000002/00000012/art00004"
doi = "doi:10.1046/j.1439-0353.2004.04793.x"
}